Alternatives to Traditional Unit Operations Are Now Available to Alleviate Very Real Logjams Due to the complexity of therapeutic protein purification, downstream bioprocess bottlenecks can arise from ...
Biomanufacturing is different from other processing industries. It is less able to sustain continuous end-to-end flows because it must contend with unique technical, practical, regulatory, and ...
Over the last few years, the number of recombinant pharmaceutical products that have entered the regulatory fray to gain approval for marketing has grown rapidly, and is now in the hundreds. As ...
Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...
New manufacturing paradigm will save 25% of total costs and Specialist Process Innovation Group created to validate approach 12 February 2018, Wales:ADC Biotechnology (ADC Bio) announces that it is ...
With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...
Osmolality is a well-established parameter for upstream bioprocessing, formulation, analytical development and QC applications throughout the manufacturing of biological drugs. A recent publication ...
Standards organization says R2v3 certification entails accurately portraying operations of facilities receiving components and materials. SERI says qualifications for a non-R2v3 downstream vendor are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback